Doctors and researchers are being urged to pay closer attention to a genetic marker that may help identify patients at risk of a life-threatening reaction to lamotrigine, a widely prescribed seizure medicine. According to new reporting from News-Medical, a marker already used to flag risk from vancomycin also appears to identify patients vulnerable to the same severe reaction when taking lamotrigine.
The finding matters because the marker is not included in the gene panels clinicians commonly order before prescribing the drug. That gap could leave some patients exposed to a rare but serious complication that might otherwise be avoided with earlier testing and better prescribing decisions. The research was reported on 2 September 2026 by a Vanderbilt Health-led team and published in JAMA Network Open. News-Medical medical news
Why the result is drawing attention
Lamotrigine is used in the treatment of epilepsy and other conditions, so any signal that improves patient safety has immediate relevance for routine care. The new finding suggests that existing pharmacogenetic tools may already contain useful information, but that current testing pathways are not always set up to capture it in time.
The key concern is not that every patient taking lamotrigine will develop a reaction. Rather, the study points to a potentially preventable risk in a subset of patients whose genetic profile may make them more vulnerable. In practical terms, that could mean more targeted screening before treatment begins, especially where clinicians already use genetic data to guide prescribing.
What clinicians may need to consider next
The report adds to a growing body of research showing that genetics can play a major role in drug safety. If the marker is validated more broadly, it could strengthen the case for reviewing pre-prescription testing in settings where lamotrigine is commonly used. It may also prompt discussions about whether existing gene panels should be updated so they better reflect real-world prescribing risks.
For now, the study is best seen as an early but important warning. It does not by itself change practice everywhere, but it raises a clear question for health systems and laboratories: if the relevant marker is already known, should it be routinely checked before the drug is prescribed?
As precision medicine continues to move into day-to-day care, findings like this show how small changes in testing can have outsized effects on patient safety. The challenge now is turning that evidence into a simpler, safer prescribing process for the patients who need it most.
Photo source: AI-generated or edited image
